Fmr LLC Purchases 804,963 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fmr LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 38.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,887,342 shares of the medical research company’s stock after acquiring an additional 804,963 shares during the period. Fmr LLC owned 1.59% of IQVIA worth $684,213,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of IQV. First Foundation Advisors increased its position in IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Invera Wealth Advisors LLC grew its stake in shares of IQVIA by 0.3% during the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after purchasing an additional 46 shares during the last quarter. Private Trust Co. NA increased its holdings in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after buying an additional 48 shares in the last quarter. Finally, Continuum Advisory LLC boosted its position in IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after buying an additional 49 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on IQV shares. BTIG Research dropped their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Morgan Stanley cut their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Finally, Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of IQV stock opened at $201.43 on Friday. The company has a market capitalization of $36.56 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company’s 50 day moving average price is $219.50 and its two-hundred day moving average price is $226.40.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.